🔥Tenaya Therapeutics (TNYA) could soar 100 % in december!
Morgan Stanley predicts significant growth for two 'Strong Buy' stocks. Tenaya Therapeutics focuses on heart disease treatment through gene therapies and precision medicines, with TN-201 in a Phase 1b trial showing potential for a 670% upside. Royalty Pharma, a royalty company in the biotech sector, has a diversified portfolio with rights to blockbuster products, aiming for long-term growth. Analysts expect strong performance from Royalty Pharma, with a potential 88% upside. Both stocks have unanimous Strong Buy ratings. Consider doing your analysis before investing.
👉Read here
Morgan Stanley predicts significant growth for two 'Strong Buy' stocks. Tenaya Therapeutics focuses on heart disease treatment through gene therapies and precision medicines, with TN-201 in a Phase 1b trial showing potential for a 670% upside. Royalty Pharma, a royalty company in the biotech sector, has a diversified portfolio with rights to blockbuster products, aiming for long-term growth. Analysts expect strong performance from Royalty Pharma, with a potential 88% upside. Both stocks have unanimous Strong Buy ratings. Consider doing your analysis before investing.
👉Read here